EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + VT3989 Sensitive: D – Preclinical osimertinib + VT3989 Sensitive : D	osimertinib + VT3989 Sensitive: D – Preclinical osimertinib + VT3989 Sensitive : D
NF2 deletion	Mesothelioma	NF2 deletion	Mesothelioma	TY-0584 Sensitive: D – Preclinical TY-0584 Sensitive : D	TY-0584 Sensitive: D – Preclinical TY-0584 Sensitive : D
WWTR1 fusion	Solid Tumor	WWTR1 fusion	Solid Tumor	IAG933 Sensitive: D – Preclinical IAG933 Sensitive : D	IAG933 Sensitive: D – Preclinical IAG933 Sensitive : D
EGFR mutation	Lung Cancer	EGFR mutation	Lung Cancer	VT-104 Sensitive: D – Preclinical VT-104 Sensitive : D	VT-104 Sensitive: D – Preclinical VT-104 Sensitive : D
EGFR exon 19 deletion	Lung Cancer	EGFR exon 19 deletion	Lung Cancer	VT-104 Sensitive: D – Preclinical VT-104 Sensitive : D	VT-104 Sensitive: D – Preclinical VT-104 Sensitive : D

TEAD inhibitor

Associations(5)